Studying changes in the incidence, diagnosis and management of GTD: The South Korean model

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 49, Issue 8, 2004, Pages 643-654

  Kim, Seung Jo ^a   Lee, Chan ^b   Kwon, So Young ^b   Na, Young Jeong ^b   Oh, Yu Kyoung ^b   Kim, Chan Ju ^b  

^a CHA University   (South Korea)

^b NONE

Author keywords

Gestational trophoblastic disease; Gonadotropins, chorionic, human; Pregnancy, molar; Trophoblastic cancer; Trophoblastic neoplasms

Indexed keywords

CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROXYUREA; METHOTREXATE; NEW DRUG; PACLITAXEL; VINCRISTINE;

AGE DISTRIBUTION; CANCER CENTER; CANCER CHEMOTHERAPY; CHA UNIVERSITY COMPREHENSIVE GYNECOLOGIC CANCER CENTER; CHEMOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DISEASE CLASSIFICATION; DRUG DEVELOPMENT; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; GENETIC ANALYSIS; GESTATIONAL TROPHOBLASTIC DISEASE; GYNECOLOGY AND OBSTETRICS CLASSIFICATION; HIGH RISK POPULATION; HUMAN; HYDATIDIFORM MOLE; INCIDENCE; LOW RISK GROUP; MAJOR CLINICAL STUDY; MODEL; MULTIMODALITY CANCER THERAPY; MULTIMODALITY THERAPY; NOMENCLATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARITY; POSITRON EMISSION TOMOGRAPHY; PREGNANCY; PREGNANCY INTERVAL; PRETREATMENT EVALUATION; PRIORITY JOURNAL; PROGNOSIS; REGISTER; REMISSION; RESEARCH INSTITUTE OF TROPHOBLASTIC DISEASE REGISTER; SCORING SYSTEM; SOUTH KOREA; THERAPY; TRANSVAGINAL ECHOGRAPHY; TROPHOBLASTIC DISEASE; TROPHOBLASTIC TUMOR; WORLD HEALTH ORGANIZATION PROGNOSTIC SCORE;

ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; INCIDENCE; KOREA; MIDDLE AGED; PARITY; PREGNANCY; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; RISK FACTORS; TERMINOLOGY; UTERINE NEOPLASMS;

EID: 4344682708     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Hertz R, Lewis JC Jr, Lipsett MB: Five years' experience with the chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in women. Am J Obstet Gynecol 1961;82:631-640
2. Bagshawe KD: Risk and prognostic factors in trophoblastic neoplasia. Cancer 1976;38:1373-1385
3. World Health Organization: Gestational Trophoblastic Disease. Geneva, WHO, 1983
4. FIGO Oncology Committee report. Int J Gynaecol Obstet 1992;39:149-150
5. Kohorn EI, Goldstein DP, Hancock BW, et al: Combining the staging system of the FIGO with the scoring system of the WHO for trophoblastic neoplasia: Report of the Working Committee of the International Gynecologic Cancer Society. Int J Gynecol Cancer 2000;10:84-88
6. Ngan HYS, Benedet JL, Bender HG, et al: FIGO staging for gestational trophoblastic neoplasia. Int J Gynaecol Obstet 2002;77:285-287
7. Benson CB, Genest DR, Bernstein MR, et al: Sonographic appearance of first trimester complete hydatidiform moles. Ultrasound Obstet Gynecol 2000;16:188-191
8. Lazarus E, Hulka C, Siewert B, Levine D: Sonographic appearance of early complete molar pregnancies. J Ultrasound Med 1999;18:589-594
9. Kim SJ, Bae SN, Kim JH, et al: Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT: 25 years experiences, KRI-TRD. Int J Gynaecol Obstet 1998;60:S85-S96
10. Kim SJ, Bae SN, Kim JH, et al: Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA/CO regimen. Gynecol Oncol 1998;71:247-253
11. Bae SN, Kim SJ: Telomerase activity in complete hydatidiform mole. Am J Obstet Gynecol 1999;180:328-333
12. Kim SJ, Park SE, Lee C, et al: Altered imprinting, promoter usage, and expression of insulin-like growth factor-II gene in gestational trophoblastic diseases. Gynecol Oncol 2003;88:411-418
13. Kim SJ, Bae SN, Kim JH, et al: Epidemiology and time trends of gestational trophoblastic disease in Korea. Int J Gynaecol Obstet 1998;60:S33-S38
14. Martin BH, Kim JH: Changes in gestational trophoblastic tumors over four decades: A Korean experience. J Gynaecol Obstet 1998;43:60-68
15. Hando T, Ohno M, Kurose T: Recent aspects of gestational trophoblastic disease in Japan. Int J Gynaecol Obstet 1998;60: S71-S76
16. Bandy LC, Clarke-Pearson DL, Hammond CB: Malignant potential of gestational trophoblastic disease at the extreme ages of reproductive life. Obstet Gynecol 1984;64:395-399
17. Berkowitz RS, Cramer DW, Bernstein MR, et al: Risk factors for complete molar pregnancy from a case control study. Am J Obstet Gynecol 1985;152:1016-1020
18. Pour Reza M, Agheli N, Vaghefi SB: Serum creatinine, urea and protein level changes in hydatidiform mole. J Am Med Assoc 1974;230:580-581
19. Berkowitz RS, Cramer DW, Bernstein MR, et al: Risk factors for complete molar pregnancy from a case control study. Am J Obstet Gynecol 1985;152:1016-1020
20. Ambani LM, Vaidya RA, Rao CS, et al: Familial occurrence of trophoblastic, disease: Report of recurrent molar pregnancies in sisters in three families. Clin Genet 1980;18:27-29
21. Lawler SD, Fisher RA, Pickthall VJ, et al: Genetic studies on hydatidiform moles: I. The origin of partial moles. Cancer Genet Cytogenet 1982;5:309-320
22. Parazzini F, Mangili G, La Vecchia C, et al: Risk factors for gestational trophoblastic disease: A separate analysis of complete and partial hydatidiform moles. Obstet Gynecol 1991;78:1039-1045
23. Lurain JR: Advances in management of high-risk gestational trophoblastic tumors. J Reprod Med 2002;47:451-459
24. Jones WB, Cardinale C, Lewis JL Jr: Management of high-risk gestational trophoblastic disease: The Memorial Hospital experience. Int J Gynecol Cancer 1997;7:27-33
25. Berkowitz RS, Goldstein DP, Bernstein MR: Modified triple chemotherapy in the management of high risk metastatic gestational trophoblastic tumors. Gynecol Oncol 1984;19:173-181
26. Newlands ES, Bagshawe KD, Begent RHJ, et al: Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high-risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol 1991;98:550-557
27. Newlands ES, Holden L, Seckl MJ, et al: Management of brain metastases in patients with high risk gestational trophoblastic tumors. J Reprod Med 2002;47:465-471
28. Halperin R, Peller S, Sandbank J, et al: Expression of the p53 gene and apotosis in gestational trophoblastic disease. Placenta 2000;21:58-62
29. KIP2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease. Lab Invest 1998;78:269-276
30. Kim HT, Choi BH, Niikawa N, et al: Frequent loss of imprinting of the H19 and IGF-II genes in ovarian tumors. Am J Med Genet 1998;80:391-395
31. Rainho CA, Pontes A, Rogatto SR: Expression and imprinting of insulin-like growth factor II and H19 genes in uterine leiomyomas. Gynecol Oncol 1999;74:375-380
32. Li HW, Taso SW, Cheung AN: Current understandings of the molecular genetics of gestational trophoblastic diseases. Placenta 2002;23:20-23
33. Relk W, Constancia M, Dean W, et al: IGF-II imprinting in development and disease. Int J Dev Biol 2000;44:145-150
34. Hao Y, Crenshaw T, Moulton T, et al: Tumor-suppressor activity of H19 RNA. Nature 1993;365:764-767
35. Vu TH, Chuyen NV, Li T, et al: Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. Cancer Res 2003;63:1999-2005
36. Yun K, Jinno Y, Sohda T, et al: Promoter-specific insulin-like growth factor 2 gene imprinting in human fetal liver and hepatoblastoma. J Pathol 1998;185:91-98
37. Issa JP, Vertino PM, Boehm CD, et al: Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc Natl Acad Sci USA 1996;93:111757-111762